At present, in vivo and in vitro studies have demonstrated the synergistic effect of FK506 and NGF in the treatment of peripheral nerve injuries (8–11); however, it remains unclear whether this effect is present in the treatment of spinal cord injury. The gene discussed is NGF; the disease is peripheral nerve injury.